Stanford Cancer Institute Clinical Trials Office Blog

We have increased our study fees for cancer industry-sponsored studies to more closely align with the amount of effort it takes to do the work. These modified fees will be included in new industry study budgets negotiated by CCTO-Finance starting on 1 September 2018. If the budget is already in negotiation, new fees will not be used.

Effective March 7, 2018, the Clinical & Translational Research Unit has corrected the service description for service line items ‘CM001’ and ‘I-CM001’ | “Infusion time, base” for both non-industry and industry studies to reflect that is does not include “IV Placement/Central Line Access”. All studies requiring infusions must also include ‘CG003’ or ‘I-CG003’ into their budgets, as they will be invoiced for IV placements/Central Line Access. Studies that were approved and/or activated in the CTRU budget builder website between July 1, 2017 and March 7, 2018 will not be billed for service line item ‘CG003’ or ‘I-CG003’ through the entirety of those specific research projects. This will be voided if the study rebudgets for any of the reasons covered in the CTRU Subsidy and Cost Recovery Policy 2017.

This does not apply to studies:

1. Approved and/or activated prior to July 1, 2017 and not submitted through the CTRU Budget Builder website.
2. Approved and/or activated after March 7, 2018

For questions and requests, please contact ctru-notify@stanford.edu and the team will be happy to assist you.

The Regulatory FAQs have been updated on the CCTO website. Get answers to the most commonly asked regulatory questions at the link: http://med.stanford.edu/ccto/services/regulatory.html#faqs